NPM1 and leukemia: According to data from a retrospective study, high-dose cytarabine plus idarubicin consolidation therapy had strong anti-leukemia effects in patients with fms-like tyrosine kinase (FLT3) wild-type and mutant AML that carried an nucleophosmin 1 (NPM1) mutation (Borlenghi et al., 2022).